Switch to Maraviroc and Raltegravir Combination Therapy (a Triple Class-Sparing Regimen) for the Treatment of HIV-1-Infected Patients on Suppressive Antiretroviral Regimens
Phase of Trial: Phase III
Latest Information Update: 16 Nov 2016
At a glance
- Drugs Dolutegravir (Primary) ; Maraviroc (Primary) ; Raltegravir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 10 Nov 2016 Planned End Date changed from 1 Jul 2016 to 1 Jul 2017.
- 10 Nov 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.
- 21 Aug 2013 New trial record